PHT3 Antibody

What are phosphohistidine (pHis) antibodies and why are they significant for research?

Phosphohistidine antibodies are specialized immunological tools developed to detect and study histidine phosphorylation, a non-canonical post-translational modification that has been historically challenging to investigate. Their significance stems from their ability to detect the labile phosphoramidate (P-N) bond characteristic of pHis and distinguish between the two isomeric forms: 1-phosphohistidine (1-pHis) and 3-phosphohistidine (3-pHis) .

These antibodies have enabled researchers to overcome previous technical limitations in studying histidine phosphorylation by providing tools for various immunological techniques including immunoblotting and immunofluorescence. Developing effective pHis antibodies has required innovative approaches due to the inherent instability of the phosphoramidate bond, which necessitated the use of stable phosphohistidine mimetics like phosphoryl-triazolylalanine (pTza) .

How do antibodies distinguish between 1-pHis and 3-pHis isoforms?

Antibodies distinguish between the two phosphohistidine isoforms through precise recognition of the spatial orientation of the phosphate group on the imidazole ring:

• 1-pHis antibodies: Specifically recognize phosphorylation at the N1 position

• 3-pHis antibodies: Specifically recognize phosphorylation at the N3 position

This isoform specificity is achieved through:

• Immunization with isoform-specific pTza analogues incorporated into degenerate peptide libraries

• Careful screening to eliminate cross-reactivity with other phosphoamino acids, particularly phosphotyrosine (pTyr)

• Selection of antibody clones that demonstrate heat-sensitive detection (confirming phosphoramidate bond recognition)

Early generation pan-pHis antibodies showed limitations due to cross-reactivity with pTyr, but newer isoform-specific monoclonal antibodies demonstrate remarkable selectivity . The structural basis for this discrimination has been revealed through X-ray crystallography of antibody-pHis peptide complexes .

What methodologies are used to generate isoform-specific pHis antibodies?

The generation of isoform-specific pHis antibodies involves sophisticated methodological approaches:

These methodologies have successfully yielded antibodies that can specifically recognize each pHis isoform while maintaining minimal cross-reactivity with other phosphoamino acids . Recent advances have further refined these approaches through phage display technology and structure-based engineering .

What engineering strategies improve the affinity and specificity of 3-pHis antibodies?

Engineering higher-affinity and more specific 3-pHis antibodies involves several sophisticated strategies:

• Phage display technology:

  • Humanization of rabbit monoclonal antibodies (like SC44-8) to create scaffolds suitable for phage display

  • Construction of diverse Fab phage-displayed libraries (six unique libraries reported)

  • Selection strategies specifically designed to enrich high-affinity 3-pHis binders with specificity for native 3-pHis over the stable mimetic 3-pTza

• Structure-guided engineering:

  • X-ray crystallography determination of eleven new Fab structures, including the first antibody-pHis peptide structures

  • Analysis of binding interfaces to identify key interaction residues

  • Rational modification of complementarity-determining regions (CDRs) based on structural insights

• Computational approaches:

  • Quantum mechanical calculations to understand the molecular basis of 3-pHis and 3-pTza discrimination

  • Structure-based computational design to predict beneficial mutations

  • Deep learning models for antibody sequence optimization

These approaches have yielded significant improvements, with the best engineered antibody (hSC44.20N32F L) demonstrating approximately 10-fold higher affinity for 3-pHis than the parental antibody , greatly enhancing its utility for detecting pHis proteins in mammalian cells.

How can researchers verify antibody specificity against cross-reactivity with other phosphoamino acids?

Rigorous validation of pHis antibody specificity requires a comprehensive approach:

Particularly important is the heat lability test, which exploits the thermosensitive nature of the phosphoramidate bond. Early pan-pHis antibodies showed limitations due to cross-reactivity with pTyr, but newer monoclonal antibodies demonstrate excellent specificity . For example, SC44-8 anti-3-pTza antibodies showed no detectable cross-reactivity with pTyr when properly validated .

How do structural studies inform the rational design of improved pHis antibodies?

Structural studies provide critical insights for rational antibody engineering:

• Binding pocket characterization:

  • X-ray crystallography of antibody-pHis peptide complexes reveals precise binding geometry

  • Identification of key residues forming hydrogen bonds with the phosphoramidate group

  • Analysis of water-mediated interactions contributing to binding affinity

• Structural basis for specificity:

  • Crystal structures reveal how antibodies distinguish between 1-pHis and 3-pHis

  • Structural determinants for discrimination between native pHis and pTza mimetics

  • Understanding of hydrophobic and electrostatic interactions in the binding pocket

• Structure-guided optimization:

  • Targeted modification of CDR residues that directly contact pHis

  • Rational introduction of stabilizing interactions to protect the labile P-N bond

  • Computational prediction of beneficial mutations based on structural models

The eleven new Fab structures reported in the literature, including the first antibody-pHis peptide structures , provide invaluable templates for such rational design approaches. Quantum mechanical calculations further enhance understanding of the molecular basis for discrimination between pHis and its mimetics , guiding the development of antibodies with improved properties for recognizing native pHis in biological samples.

What specialized protocols preserve pHis during sample preparation for immunoblotting?

Preserving the labile pHis modification during sample preparation requires specialized protocols:

The heat lability of pHis makes the parallel preparation of heated samples (95°C, 10 min) crucial as a negative control. Authentic pHis signals will disappear after heating, while other phosphoamino acid signals remain . Including positive controls (in vitro phosphorylated NME1 for 1-pHis or PGAM for 3-pHis) on each blot provides additional validation .

How should in vitro phosphorylation assays be designed to generate pure 1-pHis or 3-pHis standards?

Generating pure isoform-specific pHis standards requires careful assay design:

For 1-pHis generation:

• Enzyme system: NME1/NME2 (nucleoside diphosphate kinases)

• Reaction conditions: ATP as phosphodonor, Mg²⁺ as cofactor

• Verification: LC-MS/MS confirmation of phosphorylation at the correct histidine position

• Quality control: Heat lability testing to confirm phosphoramidate bond formation

For 3-pHis generation:

• Enzyme system: PGAM (phosphoglycerate mutase) with 2,3-BPG (2,3-bisphosphoglycerate)

• Autophosphorylation: PGAM is both enzyme and substrate, with phosphorylation occurring at His11

• Verification: LC-MS/MS confirmation of phosphorylation at His11

• Controls: H11A mutant PGAM should show no phosphorylation

These systems provide reliable sources of pure isoform-specific pHis proteins for antibody validation and as positive controls in experiments . The generation of authentic pHis standards is crucial for validating antibody specificity and for calibrating detection methods in various experimental platforms.

How can computational approaches accelerate pHis antibody development?

Computational approaches offer powerful methods for accelerating pHis antibody development:

• Deep learning for sequence generation:

  • Training on large datasets of antibody sequences (>30,000 human antibodies)

  • Generation of novel antibody variable regions with optimized properties

  • Filtering for "medicine-likeness" and humanness scores (>90th percentile)

  • Creation of diverse antibody libraries (100,000 sequences reported) in silico

• Structure-based computational design:

  • Virtual histidine scanning to identify positions for pH-dependent binding

  • Assisted Design of Antibody and Protein Therapeutics (ADAPT) platform for antibody engineering

  • Dual-pH optimization strategies for selective binding under specific conditions

• Integrated computational-experimental validation:

  • Generation and testing of small sets of designs (51 diverse antibodies reported)

  • Experimental validation of key properties: expression, monomer content, thermal stability

  • Assessment of biophysical attributes: hydrophobicity, self-association, non-specific binding

These computational approaches have demonstrated success in generating antibodies with favorable biophysical properties and pH-dependent binding behavior (up to 25-fold selectivity improvement) , suggesting promising applications for developing next-generation pHis antibodies with enhanced specificity and stability.

How do pHis antibody responses correlate with clinical outcomes in cancer patients?

Analysis of clinical data reveals significant correlations between PHF3-specific antibody responses and patient outcomes:

A study of glioblastoma multiforme (GBM) patients demonstrated remarkably high frequency of natural antibody responses against PHF3, with antibodies detected in 24 of 39 patients (61.53%) . This represents one of the highest reported rates for a specific antibody response in SEREX (serological analysis of recombinant cDNA expression libraries) studies .

Most significantly, GBM patients with detectable PHF3-specific antibodies showed statistically better survival compared to patients without such antibodies . This suggests that:

• The immune system naturally recognizes PHF3 in many GBM patients

• This immune recognition correlates with improved clinical outcomes

• PHF3 antibodies may have potential as prognostic biomarkers

The underlying mechanisms for this correlation remain under investigation, but may involve immune-mediated tumor control, as PHF3 expression was found to be concentrated in cells surrounding necroses in GBM tissues . These findings highlight the potential clinical relevance of specific antibody responses in cancer patients and suggest avenues for further investigation of antibody-based diagnostics and therapeutics.

How can pH-dependent antibodies be engineered for targeted cancer therapeutics?

Engineering pH-dependent antibodies offers a promising approach for enhancing tumor targeting:

The acidic microenvironment of solid tumors (typically pH 6.5-6.9) compared to normal tissues (pH 7.3-7.4) provides a potential targeting mechanism . Structure-based computational approaches have successfully engineered antibodies with pH-dependent binding:

• Engineering approach:

  • Implementation of dual-pH histidine-scanning mutagenesis

  • Affinity maturation platform for pH selectivity optimization

  • Structure-guided selection of histidine substitution positions

• Performance metrics:

  • Binding selectivity toward acidic pH improved by up to 25-fold versus parental antibodies

  • High affinity maintained at tumor-relevant acidic pH

  • Significantly reduced binding at physiological pH of normal tissues

• Functional validation:

  • IgG1/k full-size antibodies retained pH-dependent properties

  • Inhibition of tumor spheroid growth at acidic pH comparable to benchmark antibodies

  • Significantly reduced activity at physiological pH, potentially reducing off-target effects

This approach demonstrates the feasibility of computational optimization of antibodies for selective targeting of acidic environments, with potential applications in reducing toxicity to normal tissues while maintaining therapeutic efficacy at tumor sites .

How might deep learning transform antibody engineering beyond current capabilities?

Deep learning approaches are poised to revolutionize antibody engineering:

Recent advances demonstrate the feasibility of generating entire libraries of human antibody variable regions with favorable developability properties using deep learning algorithms . This approach offers several potential advantages:

• Scale and efficiency:

  • Generation of 100,000 variable region sequences from training datasets of ~31,000 human antibodies

  • Computational screening for favorable properties before experimental testing

  • Significant reduction in time and resources compared to conventional methods

• Developability optimization:

  • Selection for "medicine-likeness" resembling marketed antibody therapeutics

  • High expression, monomer content, and thermal stability

  • Low hydrophobicity, self-association, and non-specific binding

• Future applications:

  • Integration with antigen-specific binding design algorithms

  • Potential for fully computational antibody discovery against difficult targets

  • Expansion of the druggable antigen space to include targets refractory to conventional methods

These computational approaches could significantly accelerate the development of next-generation pHis antibodies by enabling rapid exploration of sequence space and multi-parameter optimization of binding, specificity, and developability properties simultaneously .

What novel applications might emerge from improved phosphohistidine-specific antibodies?

As phosphohistidine-specific antibodies continue to improve, several novel applications are emerging:

• Phosphoproteomics expansion:

  • Comprehensive mapping of the "phosphohistidinome" in various cell types and tissues

  • Integration of pHis data with other phosphorylation networks

  • Discovery of previously unrecognized signaling pathways involving pHis

• Diagnostic applications:

  • Development of pHis-based biomarkers for disease detection, as suggested by PHF3 antibody correlations with GBM survival

  • Use of pHis patterns to classify tumor subtypes or predict treatment responses

  • Creation of diagnostic assays for conditions with altered histidine phosphorylation

• Therapeutic targeting:

  • Development of inhibitors targeting enzymes involved in pHis metabolism

  • pH-dependent antibodies for selective tumor targeting

  • Combination approaches integrating pHis targeting with existing therapies

• Structural biology:

  • Further characterization of antibody-pHis interactions at atomic resolution

  • Development of crystallization chaperones for pHis-containing proteins

  • Structure-based drug design targeting pHis-mediated interactions

The continued improvement of these research tools will enable more comprehensive investigation of histidine phosphorylation in normal physiology and disease, potentially uncovering new diagnostic and therapeutic opportunities .